Dragonfly Therapeutics is pioneering innovative therapies that leverage the body's immune system, specifically through its proprietary platforms: TriNKET® and CYTOKINE. The TriNKET® platform focuses on creating tri-specific immune engagers that redirect natural killer (NK) cells and T cells to target and eliminate diseased cells across various conditions, including autoimmune diseases and cancers. This approach not only enhances the immune response but also aims to provide a favorable safety profile, making it a promising option for patients with limited treatment alternatives. The company has developed multiple drug candidates, including DF9001, which targets EGFR and engages immune effector cells, demonstrating superior anti-tumor activity compared to existing therapies.

In addition to TriNKETs®, Dragonfly's CYTOKINE platform is designed to produce engineered cytokines with extended half-lives, allowing for less frequent dosing while maximizing therapeutic benefits. For instance, DF6215, an engineered IL-2 cytokine, has shown enhanced efficacy in stimulating anti-tumor immune responses without the adverse effects commonly associated with traditional IL-2 therapies. Both platforms are designed to work synergistically with existing immunotherapies and traditional treatments, expanding the therapeutic options available to patients and addressing significant unmet medical needs in oncology and other disease areas.

United States

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com.

Dragonfly Therapeutics

Company Details